Saltar al contenido
Merck

Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2014-10-30)
V van Drongelen, E M Haisma, J J Out-Luiting, P H Nibbering, A El Ghalbzouri
RESUMEN

Atopic dermatitis is an inflammatory skin disease that is characterized by a reduced skin barrier function, reduced filaggrin (FLG) expression as well as increased colonization by Staphylococcus aureus. This study focused on the possible involvement of FLG in epidermal colonization by S. aureus and/or whether it affects the epidermal defence mechanisms, including the expression of antimicrobial peptides (AMPs) and enzymes involved in stratum corneum barrier lipid synthesis. Furthermore, IL-31 has been shown to reduce FLG expression, but its effects on bacterial colonization and on the expression of AMPs and enzymes involved in the barrier lipid synthesis are not known. We established N/TERT-based epidermal models (NEMs), after FLG knockdown (FLG-KD) and/or cultured with IL-31, that were colonized with S. aureus for 24 h. Both FLG-KD and IL-31 supplementation resulted in significantly increased epidermal S. aureus colonization, as well as in an up-regulation of S. aureus-induced IL-8 expression. IL-31, but not FLG-KD, prevented S. aureus-induced up-regulation of mRNA expression for the AMPs human β-defensin 2 and -3 and RNAse7, whereas psoriasin expression remained unchanged. Furthermore, the S. aureus colonization induced changes in mRNA expression of ELOVL4 was not affected by FLG-KD, but was blocked by IL-31. Expression of SCD-1 and Gcase mRNA was reduced by IL-31, but not by FLG-KD. This study shows that NEMs, with FLG-KD and/or cultured in the presence of IL-31, mimic the skin of patients with atopic dermatitis in several aspects, including enhanced bacterial colonization, increased inflammatory and reduced protective responses.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Glicerol, ACS reagent, ≥99.5%
Sigma-Aldrich
Glicerol, Molecular Biology, ≥99.0%
Sigma-Aldrich
Glicerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
N-Hydroxysuccinimide, 98%
Sigma-Aldrich
Cloruro de calcio solution, BioUltra, Molecular Biology, ~1 M in H2O
Sigma-Aldrich
Hydrocortisone, BioReagent, suitable for cell culture
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Glicerol, ≥99.5%
Sigma-Aldrich
α-Linoleic acid, ≥98%
Sigma-Aldrich
Calcium chloride, anhydrous, BioReagent, suitable for insect cell culture, suitable for plant cell culture, ≥96.0%
Sigma-Aldrich
Glicerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Hydrocortisone, γ-irradiated, powder, BioXtra, suitable for cell culture
Sigma-Aldrich
Glicerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Hydrocortisone, ≥98% (HPLC)
Sigma-Aldrich
Glicerol, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Supelco
Glicerol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicerol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Ácido linoleico, liquid, BioReagent, suitable for cell culture
USP
Glicerol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Arachidonic acid, >95.0% (GC)
Sigma-Aldrich
Glicerol, FCC, FG
Sigma-Aldrich
Calcium chloride, powder, 99.99% trace metals basis
Sigma-Aldrich
Glicerol, meets USP testing specifications
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Cloruro de calcio dihydrate
Sigma-Aldrich
Arachidonic acid, from non-animal source, ≥98.5% (GC)
Supelco
Hydrocortisone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Selenous acid, 98%